Initial nivolumab-based treatment halts melanoma progression

Bookmark and Share
Published: 1 Jun 2015
Views: 4929
Dr Jedd Wolchok - Memorial Sloan-Kettering Cancer Center, New York, USA

Dr Wolchok talks to ecancertv at ASCO 2015 about results from a randomised phase III trial which indicate that initial therapy with nivolumab alone or in combination with ipilimumab is significantly more effective than ipilimumab alone.

These results represent yet another major step forward in tackling melanoma.

Read the news article or watch the press conference for more.

ecancer's filming at ASCO has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.